MYCN-Driven Metabolic Networks Are a Critical Dependency of High-Risk Neuroblastomas
Cancers · 08.10.2025 · 17 (19) · 3256
DOI: 10.3390/cancers17193256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.10.2025. Verfasst von Michelle G Pitts und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Kentucky, Lexington, KY 40536, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, V Foundation for Cancer Research, NIH HHS.
Abstract (Originalsprache)
Neuroblastoma is a devastating pediatric solid tumor that, despite significant recent advances, still accounts for nearly 15% of all childhood cancer deaths. Patients are risk stratified based on a number of features, including amplification of the MYCN oncogene, yet targeting MYCN itself has been unsuccessful to date. The complex interplay between this oncogene and its many metabolic targets has proven challenging and is only beginning to be understood in the context of pediatric tumors. It is increasingly recognized, however, that MYCN-driven metabolic rewiring and concomitant increases in biosynthetic precursors has the potential to drive many aspects of tumor development. Furthermore, emerging research suggests that improving overall therapeutic outcomes for neuroblastoma patients may well require individual metabolic profiling, allowing personalized simultaneous targeting of multiple metabolic nodes. In this review, we outline clinically relevant research involving MYCN-driven metabolic derangements, including increased glucose uptake, polyamine synthesis, glycosylation, and others, and attempt to summarize the influence of MYCN on important metabolic genes and druggable protein targets. We spotlight emerging research in glycosylation and its modulation as an often overlooked but increasingly promising therapeutic area. It is our hope that this document will provide utility for both clinicians and scientists seeking to understand how the MYCN oncogene and metabolism are critically intertwined.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Kentucky, Lexington, KY 40536, USA.
- Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
ORCID-Profile: Michelle G Pitts, Michael D Buoncristiani
Förderung
- NIGMS NIH HHS
- V Foundation for Cancer Research
- NIH HHS
- University of Kentucky Center for Cancer and Metabolism
- Dick Vitale Pediatric Cancer Research Fund
Zitieren
APA
Pitts, M. G., Bryant, L. T., Buoncristiani, M. D., & Rellinger, E. J. (2025). MYCN-Driven Metabolic Networks Are a Critical Dependency of High-Risk Neuroblastomas. Cancers, 17(19), 3256. https://doi.org/10.3390/cancers17193256
Vancouver
Pitts MG, Bryant LT, Buoncristiani MD, Rellinger EJ. MYCN-Driven Metabolic Networks Are a Critical Dependency of High-Risk Neuroblastomas. Cancers. 2025;17(19):3256. doi:10.3390/cancers17193256
BibTeX
@article{Pitts2025,
author = {Pitts, Michelle G and Bryant, Lindsay T and Buoncristiani, Michael D and Rellinger, Eric J},
title = {MYCN-Driven Metabolic Networks Are a Critical Dependency of High-Risk Neuroblastomas},
journal = {Cancers},
year = {2025},
volume = {17},
number = {19},
pages = {3256},
doi = {10.3390/cancers17193256}
}
EUVIMED